7/30/2019 Anti Retroviral Therapy guidelines
1/152
ANTIRETROVIRAL THERAPY
OF HIV INFECTION IN INFANTS
AND CHILDREN:
TOWARDS UNIVERSAL ACCESS
Recommendations
for a public health approach
Strengthening health services to fght HIV/AIDSHIV/AIDS Programme
7/30/2019 Anti Retroviral Therapy guidelines
2/152
World Health Organization 2006
All r ights reserved. Publications o the World Health Organization can be obtained rom WHO Press, World Health
Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; ax: +41 22 791 4857; email:
[email protected]). Requests or permission to reproduce or translate WHO publications whether or sale or or
noncommercial distribution should be addressed to WHO Press, at the above address (ax: +41 22 791 4806;
email: [email protected]).
The designations employed and the presentation o the material in this publication do not imply the expression o
any opinion whatsoever on the part o the World Health Organization concerning the legal status o any country,
territory, city or area or o its authorities, or concerning the delimitation o its rontiers or boundaries. Dotted lines on
maps represent approximate border lines or which there may not yet be ull agreement.
The mention o specifc companies or o certain manuacturers products does not imply that they are endorsed or
recommended by the World Health Organization in preerence to others o a similar nature that are not mentioned.
Errors and omissions excepted, the names o proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to ver iy the inormation conta ined in this publication. However,
the published material is being distributed without warranty o any kind, either express or implied. The responsibilit y
or the interpretation and use o the material lies with the reader. In no event shall the World Health Organization be
liable or damages arising rom its use.
7/30/2019 Anti Retroviral Therapy guidelines
3/152
ANTIRETROVIRAL THERAPYOF HIV INFECTION IN INFANTS
AND CHILDREN:
TOWARDS UNIVERSAL ACCESS
Recommendationsfor a public health approach
2006
7/30/2019 Anti Retroviral Therapy guidelines
4/152
ii
7/30/2019 Anti Retroviral Therapy guidelines
5/152
iii
Abbreviations. iv
I. Introduction. 1II. Objectives.o.the.Guidelines. 2
III. Development.o.the.Guidelines. 3
IV. Establishing.Diagnosis.o.HIV.Inection. 5
V. When.to.Start.Antiretroviral.Therapy.in.Inants.and.Children.11
VI. What.to.Start..Recommended.First-Line.ARV.Regimens.in.Inants.and.Children. 18
VII. Considerations.or.ART.in.Inants.Previously.Exposed.to.ARV.Drugs. 26
VIII. Antiretroviral.Drug.Toxicity. 28
IX. Substituting.Within.a.First-Line.ARV.Regimen.in.Inants.and.Children.because.o.Drug.Toxicity. 31
X. Switching.an.ARV.Regimen.in.Inants.and.Children:.Treatment.Failure. 33
XI. Choice.o.ARV.Regimens.in.the.Event.o.Treatment.Failure.o.First-Line.Regimens.in..Inants.and.Chi ldren..Second-Line.Regimens. 39
XII. Considerations.or.Inants.and.Children.Coinected.With.Tuberculosis.and.HIV. 43
XIII. Considerations.or.Nutrition.in.HIV-Inected.Inants.and.Children. 50
XIV. Considerations.or.ART.in.Adolescents. 53
XV. Clinical.and.Laboratory.Monitoring. 55
XVI. Adherence.to.ART. 59
XVII. Strategies.in.the.Event.o.Failure.o.Second-Line.Regimens. 62
XVIII.Drug.Resistance. 64
Annex.A:. Members.o.the.technical.reerence.group.on.paediatric.HIV.care.and.treatment. 66
Annex.B:. Par t.A:.WHO.cl inical.staging.o.HIV.or.inants.and.children..with.established.hiv.inection. 68
Annex.B:. Par t.B:.Presumptive.and.denitive.criteria.or.recognizing.HIV.related.clinical..events.in.inants.and.children.with.established.HIV.inection. 70
Annex.C:. WHO.classication.o.HIV-associated.immunodeciency.in.inants.and.children. 77
Annex.D:. 12-Month.mortality.risk.at.selected.thresholds.or.%CD4+,..absolute.CD4.count.and.total.lymphocyte.count.by.age. 78
Annex.E:. Prescribing.inormation.and.weight.based.dosing.o.available.ARV.ormulations. .or.inants.and.children. 79
Annex.F:. Serious.acute.and.chronic.toxicities.caused.by.ARV.drugs,.possibly.requiring..therapy.modication:.clinical.presentation,.laboratory.abnormalities.and.implications.or.ART.management.117
Annex.G:. Severity.grading.o.selected.clinical.and.laboratory.toxicities..most.commonly.seen.with.recommended.ARV.drugs.or.children.121
Annex.H:. Sexual.maturi ty.rating.(Tanner.staging).in.adolescents. 127
Annex.I:. Recommended.tiered.laborator y.capabilit ies.or.ART.monitoring.in..resource-limited.settings 129
Reerences 130
CONTENTS
7/30/2019 Anti Retroviral Therapy guidelines
6/152
ivAntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
AbbREVIATIONS
3TC. lamivudine
Ab. antibodyABC. abacavirACTG. AIDS.clinical.trials.groupAFB. acid-ast.bacilliAIDS. acquired.immunodeciency.
syndromeALT. alanine.aminotranserase.a.m.. ante.meridiem.(denotes.morning)
ART. antiretroviral.therapyARV. antiretroviral.(drug)AST . aspartate.aminotranseraseAUC. area.under.curveAZ T. zidovudine.(also.known.as.ZDV)BAL. bronchoalveolar.lavageb.d.. twice.dailyBSA . body.surace.areaCD4+. T-lymphocyte.bearing.CD4.receptorCHAP. Children.with.HIV.Antibody.
Prophylaxis.(clinical.trial)CMV . cytomegalovirusCNS. central.nervous.systemCPK. creatinine.phosphokinaseCPT. co-trimoxazole.preventive.therapyCRAG. cryptococcal.antigenCSF. cerebrospinal.fuid
CT. computerized.tomographyCTX. co-trimoxazoleCXR . chest.X-rayd4T. stavudineDART. Development.o.Antiretroviral.
Therapy.(in.Arica)DBS. dried.blood.spot.ddI. didanosineDNA. deoxyribonucleic.acidDOT. directly.observed.therapyEFV. eavirenzEIA. enzyme.immunoassayEMEA. European.Medicines.Agency.
ELISA. enzyme-linked.immunosorbent.assay.
FBC. ull.blood.countFDA. Food.and.Drug.AdministrationFDC. xed-dose.combinationFTC. emtricitabineGI. gastrointestinalHDL. high-density.lipoproteinHgb. haemoglobinhgc . hard.gel.capsuleHIV. human.immunodeciency.virusHIVDR . HIV.drug.resistanceHIVNET. HIV.Network.or.Prevention.TrialsHIVResNet. Global.HIV.Drug.Resistance.
NetworkHPPMCS. HIV.Paediatric.Prognostic.Markers.
Collaborative.StudyHSV . herpes.simplex.virus
ICD . immune.complex.dissociated
IDV . indinavirIMCI. integrated.management.o.childhood.illness
INH. isoniazidIRIS. immune.reconstitution.
infammatory.syndromeLDH. lactic.dehydrogenase.LDS. lipodystrophy.LGE . lineal.gingival.erythema.LIP . lymphocytic.interstitial.pneumoniaLPV. lopinavirLTB. laryngotracheal.bronchitisMRI . magnetic.resonance.imagingMTCT. mother-to-child.transmission.(o.HIV)NFV. nelnavir.NNRTI. non-nucleoside.reverse.
transcriptase.inhibitorNPA. nasopharyngeal.aspirateNRTI. nucleoside.reverse.transcriptase.
inhibitorNVP. nevirapineOHL. oral.hairy.leukoplakiaPACTG. Paediatric.AIDS.Clinical.Trials.GroupPCP. Pneumocystis.pneumoniaPCR. polymerase.chain.reaction
PENTA. Paediatric.European.Network.or.Treatment.o.AIDS.PGL. persistent.generalized.
lymphadenopathyPI. protease.inhibitorp.m.. post.meridiem.(denotes.aternoon)PML. progressive.multiocal.
leukoencephalopathyPMTCT. prevention.o.mother-to-child.
transmission.(o.HIV)/r. low-dose.ritonavirRDA . recommended.daily.allowanceRNA. ribonucleic.acid.
RT. reverse.transcriptase.RTI. reverse.transcriptase.inhibitorRTV. ritonavirRTV-PI. ritonavir-boosted.protease.inhibitorSD. standard.deviation.SJS. Stevens-Johnson.syndromeSQV. saquinavirSTI . structured.treatment.interruptionTB. tuberculosisTDF. tenoovir.disoproxil.umarateTEN . toxic.epidermal.necrolysisTLC . total.lymphocyte.countTRG . Technical.Reerence.GroupULN. upper.limit.o.normalUp24 Ag. ultrasensitive.p24.antigenURTI. upper.respiratory.tract.inectionWBC. white.blood.cell.countWHO. World.Health.Organization
7/30/2019 Anti Retroviral Therapy guidelines
7/152
The.most.ecient.and.cost-eective.way.to.tackle.paediatric.HIV.globally.is.to.reduce.mother-
to-child.transmission.(MTCT).However,.every.day.there.are.nearly.1500.new.inections.in.children.under.15.years.o.age,.more.than.90%.o.them.occurring.in.the.developing.world.and.most.being.associated.with.MTCT.(1).HIV-inected.inants.requently.present.with.clinical.symptoms.in.the.rst.year.o.lie,.and.by.one.year.o.age.an.estimated.one-third.o.inected.inants.will.have.died,.and. about. hal. by.2. years.o. age. (2,.3).There. is.thus.a. critical. need. to.provide. antiretroviral.therapy.(ART). or.inants.and.children.who.become.inected.despite.the.eorts.being.made.to.prevent.such.inections.
In.countries.where.it.has.been.successully.introduced,.ART.has.substantially.changed.the.ace.o.HIV.inection.HIV-inected.inants.and.children.now.survive. to.adolescence.and.adulthood.
The.challenges.o.providing.HIV.care.have.thereore.evolved.to.become.those.o.chronic.as.well.as. acute. care. In. resource-limited. settings,. many. o. which. are. countries. hardest. hit. by. the.epidemic,.unprecedented.eorts.made.since.the.introduction.o.the.3.by.5.targets.and.global.commitments.to.rapidly.scale.up.access.to.ART.have.led.to.remarkable.progress.However,.this.urgency.and.intensity.o.eort.have.met.with.less.success.in.extending.the.provision.o.ART.to.HIV-inected. children. Signicant. obstacles. to. scaling. up. paediatric. care. remain,. including.limited.screening.or.HIV,.a.lack.o.aordable.simple.diagnostic.testing.technologies,.a.lack.o.human.capacity,.insucient.advocacy.and.understanding.that.ART.is.ecacious.in.children,.limited.experience.with.simplied.standardized.treatment.guidelines,.and.a.lack.o.aordable.
practicable.paediatric.antiretroviral.(ARV).ormulations.Consequently,.ar.too.ew.children.have.been. started. on. ART. in. resource-limited. settings. Moreover,. the. need. to.treat. an.increasing.number.o.HIV-inected.children.highlights.the.primary.importance.o.preventing.the.transmission.o.the.virus.rom.mother.to.child.in.the.rst.place.
WHO.guidelines.or.the.use.o.ART.in.children.were.considered.within.the.guidelines.or.adults.published.in.2004.(4).Revised,.stand-alone.comprehensive.guidelines.based.on.a.public.health.approach.have.been.developed.in.order.to.support.and.acilitate.the.management.and.scale-up.o.ART.in.inants.and.children
The.present.guidelines.are.part.o.WHOs.commitment.to.achieve.universal.access.to.ART.by.2010.
Related. publications. include. the. revised. treatment. guidelines. or. adults. (ie. the. 2006. revision),.revised.guidelines.on.ARV.drugs.or.treating.pregnant.women.and.preventing.HIV.inection.in.inants,.guidelines.on.the.use.o.co-trimoxazole.preventive.therapy.(CPT),(i).and.revised.WHO.clinical.staging.or.adults.and.children.(5).
(i). These.three.documents.are.available.at.http://wwwwhoint/hiv/pub/guidelines/en.
1. INTRODUCTION
7/30/2019 Anti Retroviral Therapy guidelines
8/152
2AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
These.stand-alone.treatment.guidelines.serve.as.a.ramework.or.selecting.the.most.potent.and.
easible.rst-line.and.second-line.ARV.regimens.as.components.o.expanded.national.responses.or.the.care.o.HIV-inected.inants.and.children.Recommendations.are.provided.on:.
. diagnosing.HIV.inection.in.inants.and.children;.
. when. to.start. ART,.including. situations. where.severe.HIV. disease. in.children. less.than.18.months.o.age.has.been.presumptively.diagnosed;.
. clinical.and.laboratory.monitoring.o.ART;.
. substitution.o.ARVs.or.toxicities.
The.guidelines.consider.ART.in.dierent.situations,.eg.where.inants.and.children.are.coinected.with.HIV.and.TB.or.have.been.exposed.to.ARVs.either.or.the.prevention.o.MTCT.(PMTCT).or.because.o.breasteeding.rom.an.HIV-inected.mother.on.ART.They.address.the.importance.o.nutrition.in.the.HIV-inected.child.and.o.severe.malnutrition.in.relation.to.the.provision.o.ART.Adherence.to.therapy.and.viral.resistance.to.ARVs.are.both.discussed.with.reerence.to.inants.and.children.A.section.on.ART.in.adolescents.briefy.outlines.key.issues.related.to.treatment.in.this.age.group.
WHO strongly recommends that Paediatic ormulations including fxed dose combinations
(FDC) o ARVs be made available by the Pharmaceutical Industry. Consultation betweenpar tners including the Pharmaceutical Industry and medecines regulator y authorities will
be pursued in a separate process. This guideline does not thereore cover the specifc
needs or ARV drug development.
WHO.recognizes.the.need.to.strengthen.health.systems,.including.human.resources.capacity.and.monitoring.capabilities,.with.a.view.to.maximizing.the.quality.and.long-term.benets.o.therapy.Improved.access.to.HIV.diagnostic.testing.as.well.as.to.immunological.assays.or.measuring.%.CD4+.or.absolute.CD4.cell.counts.or.inants.and.young.children.is.important.or.
assisting. in. decision-making. on. initiation. and. optimizing. ART. The. inability. to. diagnose. HIV.inection.early.in.children,.severely.limits.access.to.ART.and/or.its.timely.initiation.
This. publication. is. primarily. intended. or. use. by. treatment. advisory. boards,. national. AIDS.programme. managers. and. other. senior. policy-makers. who. are. involved. in. the. planning. o.national.and.international.HIV.care.strategies.or.children.in.resource-limited.countries.
The.major.limitation.in.developing.these.guidelines.is.the.lack.o.appropriate.ARV.ormulations.or.use.in.children,.and.in.certain.situations.the.only.available.option.may.be.to.use.ARV.products.intented.or.adult.use
II. ObjECTIVES OF THE GUIDELINES
7/30/2019 Anti Retroviral Therapy guidelines
9/152
3
III. DEVELOPmENT OF THE GUIDELINES
Since.the.original.guidance.on.ART.or.inants.and.children.became.available.in.2004.there.have.
been.advances.in.the.diagnosis.and.treatment.o.HIV,.and.data.have.emerged.on.ecacy,.resistance,.drug-drug.interactions.and.the.long-term.toxicities.o.ART.based.on.use.in.resource-limited.settings.At.a.consultation.o.the.Technical.Reerence.Group.on.Paediatric.HIV.Care.and.Treatment. (TRG). in.Geneva. on. 2021.June. 2005,.experts.reviewed. and.assessed. scientic.evidence.and.experiences.in.the.scaling.up.o.paediatric.ART.and.HIV. care.This.consultation.provided.the.basis.or.the.present.recommendations.In.giving.their.advice.the.experts.considered.the.ollowing.overarching.principles
. ART. programmes. should. be. scaled. up. with. a. view. to. universal. access,. ie. all. persons,.including.inants.and.children,.requiring.treatment.as.indicated.by.medical.criteria.should.
have.access. to.it,.and.the. treatment. o.inants. and. children.in. need. o.ART. according.to.national.and.international.guidelines.should.begin.as.soon.as.is.practicable
. To. support. implementation,. ARV. regimens. should. be. standardized. and. simplied. The.recommendations.in.these.guidelines.are.harmonized.with.the.WHO.guidelines.on.treatment.in.adults,. ARVs. or. treating.pregnant.women. and. preventing. MTCT. o.HIV. to.inants,.and.post-exposure.prophylaxis.
. ART.recommendations.should.be.based.on.the.best.available.scientic.evidence,.avoiding.the.use.o.substandard.protocols.that.compromise.the.outcomes.o.individual.patients.and.
creating.a.potential.or.the.emergence.o.drug-resistant.virus,.and.on.regimens.that.both.oer.a.durable.response.and.preserve.uture.treatment.options
. The. recommendations. should. be. based. on. evidence. rom. randomized. controlled. trials,.high-quality. scientic. studies. or. non-treatment. related. options,. or. observational. cohort.data,.or,.i.insucient.evidence.is.available,.on.expert.opinion,.and.they.should.be.identied.as.such.The.strength.o.the.recommendations.has.been.indicated.as.a.guide.to.the.degree.to.which.they.should.be.considered.by.country.programmes.(Table.1).
. Cost-eectiveness.was.not.explicitly.considered.as.part.o.these.recommendations,.although.the.realities.with.respect.to.the.availability.o.human.resources,.health.system.inrastructures.
and.socioeconomic.contexts.were.taken.into.account
. Revisions.to.existing.recommendations.should.not.disrupt.the.scale-up.eorts.already.under.way.in.countries.Adaptations.in.accordance.with.prevailing.local.situations.may.be.necessary.in.order.to.acilitate.implementation
Following.the.production.o.drat.guidelines.by.the.designated.writing.committee,.the.document.was.sent.to.institutional.and.organizational.partners.worldwide.and.made.available.on.the.WHO.website.or.public.consultation.during.the.period.312.November.2005.At.a.consultation.o.the.writing. committee. in. Geneva. on. 1718. November. 2005,. all. comments. were. validated. and.
addressed,.as.appropriate,.in.the.nal.document,.which.has.been.reviewed.again.by.the.TRG.(a.list.o.TRG.members.is.provided.in.Annex.A).
7/30/2019 Anti Retroviral Therapy guidelines
10/152
4AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Table . Grading o recommendations and levels o evidence
Strength o recommendation Level o evidence to guiderecommendation
A. Recommended..should.be.ollowed
B. Consider..applicable.in.most.situations
C. Optional
I. At.least.one.randomized.controlled.trial.with.clinical,.laboratory.or.programmatic.endpoints
II. .At.least.one.high.quality.study.or.several.adequate.studies.with.clinical,.
laboratory.or.programmatic.endpoints.III. Observational.cohort.data,.one.or.more.
case.controlled.or.analytic.studies.adequately.conducted.
IV. Expert.opinion.based.on.evaluation.o.other.evidence
Source: Adapted.rom.reerences.(6).and.(7 ),.and:WHO.Evidence.Network,.http://wwweurowhoint/HEN/Syntheses/hepatitisC/20050408_5Evidence-based.medicine,.http:.//wwwebm-guidelines.com/ebmg/itkkati
7/30/2019 Anti Retroviral Therapy guidelines
11/152
This.section.summarizes.WHO.recommendations.or.establishing.the.presence.o.HIV.inection (i ).
in.order.to.ensure.that.inants.and.children.can.access.HIV.care.and.treatment.and.to.aid.clinical.management.The.denitive.diagnosis.o.HIV.inection.in.children.at.any.age.requires.diagnostic.testing. that. conrms. the. presence. o. the. human. immunodeciency. virus. Antibody. testing.identies.HIV.antibody.However,.maternal.HIV.antibody.is.transerred.passively.during.pregnancy.and.may.rarely.persist.beyond.the.rst.12.months.o.lie.in.children.born.to.HIV-inected.mothers.[8].making.the.interpretation.o.positive.HIV.antibody.test.results.dicult.In.order.to.diagnose.HIV.inection.denitively.in.children.aged.under.18.months,.assays.that.detect.the.virus.or.its.components.(ie.virological.tests).are.thereore.required.Virological.tests.that.can.be.used.in.children.include:
. assays.to.detect.HIV.DNA.[9];
. assays.to.detect.HIV.RNA.[10-14];
. assays.to.detect.p24.antigen.[15-17]
The.technology.or.virological.tests.is.oten.considered.too.costly.and.complex.or.roll-out.in.low-resource.settings.Real-time.PCR.detects.HIV-RNA.and.HIV-DNA.and.several.automated.platorms.are.commercially.available.It.has.become.cheaper.and.easier.to.standardize.than.with.previous.methods.or.PCR,.providing.several.advantages.in.the.early.diagnosis.o.HIV.inection. in. children. and. the. monitoring. o. the. eectiveness. o. ART. [13]. Ultrasensitive. p24.
(Up24Ag).assays.are.also.promising.alternatives.or.use.in.resource-constrained.settings.[18].The. evaluation. o. such. technologies. merits. urther. research. and. urgent. standardization.Regardless.o.the.testing.technology.that.will.be.introduced.on.a.wider.scale,.the.reliability.o.laboratories.should.be.continuously.ensured.with.standard.quality.assessments
Blood. may. be. dicult. to. collect. rom. young. inants. and. must. be. sent. immediately. to. the.laboratory.More.recently,.the.use.o.dried.blood.spots.(DBSs).or.both.HIV-DNA.or.HIV-RNA.testing. and. Up24Ag. assay. has. proved. robust. and. reliable. [19-26]. DBSs. do. not. require.venepuncture.but.can.be.obtained.by.using.blood.rom.a.nger-stick.or.heel-stick.They.carry.a.smaller.biohazard.risk.than.liquid.samples,.are.stable.at.room.temperature.or.prolonged.periods.
and. are. easier. to. ship,. thus. acilitating. centralized. laboratory. testing. [19]. The. use. o. DBSs.should.be.more.widely.implemented.in.order.to.improve.access.to.virological.testing.in.a.range.o.resource-limited.settings.
National.programmes.in.charge.o.PMTCT.and.the.provision.o.ART.should.strive.to.ensure.that.diagnostic.protocols.are.in.place.or.systematic.testing.o.HIV-exposed.inants.and.children,.and.o.symptomatic.children.where.HIV.is.suspected,.including.the.availability.o.virological.tests.that.allow.early.diagnosis.o.HIV.inection.in.young.children.The.identication.and.ollow-up.o.inants.born.to.HIV-inected.women.are.a.necessary.rst.step.in.inant.diagnosis.It.needs.to.be.emphasized.that.children.under.18.months.o.age.who.are.known.or.suspected.to.have.been.exposed.to.HIV.
should.be.closely.monitored.and.should.benet.early.in.lie.rom.interventions.such.as.CPT,.even.where.virological.testing.is.not.available.or.the.denitive.diagnosis.o.HIV.inection.
i. Technical.recommendations.on.diagnosis.and.case.denitions.or.HIV.inection.in.inants.and.children.are.published.separately.and.are.being.updated.in.2006.
IV. ESTAbLISHING DIAGNOSIS OF HIV INFECTION
7/30/2019 Anti Retroviral Therapy guidelines
12/152
AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
In.children.aged.18.months.or.more,.HIV.antibody.tests,.including.rapid.antibody.tests.(either.
rapid.HIV.tests.or.laboratory.based.HIV.antibody.enzyme.immunoassays.[EIAs].or.a.combination.o.both),.can.be.reliably.used.to.diagnose.HIV.inection.denitively.in.the.same.manner.as.they.are.used.in.adults(i )
While.HIV.antibody.testing.cannot.be.used.to.diagnose.HIV.inection.denitively.in.inants.under.18.months.o.age,.it.can.be.useul.or.identiying.potentially.uninected.inants.as.early.as.9.to.12.months.o.age,.as.most.uninected.HIV-exposed.inants.lose.maternal.HIV.antibody.by.the.age.o.12.months.(see.also.section.on.breasteeding.inants)..
Additional. investment. by. governments. to. improve. access. to. earlier. HIV. diagnosis. or. inants.
could.lead.to.a.notable.increase.in.the.eciency.o.PMTCT.programmes.in.identiying.HIV-inected. children,. acilitating. medical. management,. reducing. morbidity. and. mortality. and.improving.the.quality.o.lie.In.addition,.early.diagnosis.oers.other.benets.that.extend.beyond.economic.savings.[27]
Children.may.or.may.not.have.a.living.parent.or.identied.legal.guardian.and.issues.o.consent,.competency.to.consent,.disclosure,.condentiality.and.counselling.have.to.be.considered.National.policies.need.to.be.clear.in.their.recommendations.on.how.to.provide.HIV.testing.services.to.inants.and.children,.and.programmes.should.ensure.tools.and.resources.provide.clear.specic.guidance.on.inormed.consent,.counselling,.inorming.and.disclosure.or.HIV.testing.in.children(ii).
I.HIV.inection.is.diagnosed.in.a.young.child.or.inant.the.mother.hersel.is.usually.HIV-inected.and.partners.and.other.siblings.may. also.be.inected. Appropriate.counselling.and. support. should.thereore.be.provided.to.amilies.when.testing.or.HIV.in.children.
Children aged under 8 months
Denitive.laboratory.diagnosis.o.HIV.inection.in.children.aged.under.18.months.can.only.be.made.by.conducting.virological.testing.For.the.purposes.o.clinical.management.including.the.initiation.o.ART.where.access.to.these.virological.tests.is.limited,.WHO.advises.that.the.rst.virological.testing.should.be.conducted.at.or.around.6.weeks.ollowing.birth.[28-30].Although.
earlier.virological.testing,.during.the.rst.48.hours.o.lie.o.an.HIV-exposed.inant,.can.identiy.inants.inected.in.utero,.those.inants.inected.during.late.pregnancy.and.intrapartum.will.have.negative.virological.tests.at.that.time.By.the.age.o.4.weeks,.virological.testing.approaches.98%.sensitivity. [30]. It. is. considered. more. programmatically. ecient. to. perorm. initial. virological.testing.rom.the.age.o.6.weeks.Positive.virological.testing.at.any.age,.however,.is.considered.indicative.o.HIV. inection.or.purposes.o.clinical.management.Preerably,.a. repeat.test.on.a.separate. specimen. should. be. peromed. to. conrm. an. initial. positive. test. It. is. recognized,.however,.that.in.severely.resource-constrained.settings,.repeat.virological.testing.on.either.the.same.specimen.or.a.separate.one.to.conrm.diagnosis.may.not.be.easible.or.aordable.
(i). The. precise. algorithms.or. combination.o. tests. required.to. diagnose.HIV. inection.or.diagnostic. and. surveillance.purposes.are.urther.explained.in.reerence.25
(ii). The.WHO.online. toolkit.on.HIV. testing.and.counselling.includes.a.section.o.resources.on.HIV.testing.and.counselling.in.children.and.is.available.at:.http://whoarvkitnet/tc/en/indexjsp
7/30/2019 Anti Retroviral Therapy guidelines
13/152
In.these.situations.the.reliability.o.the.laboratory.(determined.by.standard.quality.assessment).
is.undamental.to.ensure.reliable.test.results.In.children.diagnosed.with.HIV.inection.on.the.basis.o.one.positive.virological.test,.HIV.antibody.testing.should.preerably.be.perormed.ater.18.months.o.age.in.order.to.conrm.HIV.inection.(Fig.1).
By.the.age.o.12.months.most.uninected.HIV-exposed.children.have.lost.maternal.antibody,.and.testing.HIV.antibody-positive.at.this.age.can.be.considered.indicative.o.HIV.inection.(ie.945%.seroreversion.at.the.age.o.12.months).[31-33].This.should.be.conrmed.by.repeat.antibody.testing.ater.the.age.o.18.months.
Diagnosing HIV inection in breasteeding inants
I.an.inant.is.breasteeding.he.or.she.remains.at.risk.o.acquiring.HIV.inection.throughout.the.breasteeding.period.It.is.not.necessary.to.stop.breasteeding.prior.to.perorming.diagnostic.HIV.virological.testing,.but.interpreting.negative.results.is.dicult.Positive.results.should.be.considered.to.refect.HIV.inection.and.usual.conmatory.algorithms.ollowed.On.the.basis.o.expert.opinion.WHO.advises.that.the.window.period.required.beore.negative.virological.test.results.can.be.assumed.to.reliably.indicate.HIV.inection.status.ater.the.complete.cessation.o.breasteeding.is.six.weeks.For.children.who.have.continued.to.breasteed.into.the.rst.year.o.lie.the.same.six.week.window.period.is.suggested.or.serological.HIV.antibody.testing.beore.negative.test.results.reliably.indicate.HIV.inection.status.
HIV-exposed symptomatic inants and childrenWhere.virological.testing.is.not.routinely.available,.any.child.under.9-12.months.o.age.known.to.be.HIV-exposed.and.developing.signs.and.symptoms.o.HIV.inection.should.be.reerred.or.virological.testing.Positive.virological.results.in.a.symptomatic.inant.or.child.indicate.HIV.inection.
Diagnosing HIV inection where mother or inant has received ARV drugs or PMTCT
When.HIV.DNA.assays.are.used.or.diagnosis,.the.use.o.ARV.drugs.in.the.mother.or.inant.or.PMTCT.should.not.aect.the.test.result.HIV.DNA.remains.detectable.in.the.peripheral.blood.mononuclear.cells.o.HIV-inected.children.who.have.received.ART.and.have.undetectable.viral.replication.as.measured.by.HIV.RNA.assays,.and.so.HIV.DNA.testing.can.be.conducted.in.inants.who.have.received.ARV.or.MTCT.prevention.There.are.theoretical.concerns.about.the.sensitivity.o.HIV.RNA.or.Up24Ag.assays.However.experts.based.on.currently.available.data.recommend.that.the.RNA.or.Up24Ag.can.be.used.at.any.time.rom.6.weeks.o.age.[12]
Diagnosing inection when the mother is on ART
It.is.not.known.whether.maternal.ART.during.breasteeding.aects.HIV.RNA.or.Up24Ag.detection.in.inants.in.the.light.o.the.relatively.high.ART.levels.ound.in.the.inants.o.breasteeding.mothers.[34],. DNA. detection. is. unaected. by. maternal. ART. Experts. recommend. that. all. the. above.methods.o.virological.testing.can.be.used.rom.6.weeks.o.age.even.i.the.mother.is.breasteeding.
and.on.ART.
7/30/2019 Anti Retroviral Therapy guidelines
14/152
8AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Children aged 8 months and more
Denitive.HIV.diagnosis.in.children.aged.18.months.and.more.(with.known.or.unknown.HIV.exposure).can.be.made.with.antibody.tests,.including.rapid.antibody.tests.ollowing.standard.testing.algorithms.used.or.adults.(Fig.1).The.conrmation.o.a.positive.antibody.test.result.should.ollow.standard.national.testing.algorithms,.and.at.a.minimum.should.involve.duplicate.testing.by.means.o.a.dierent.HIV.antibody.test.[35,.36].The.use.o.rapid.antibody.tests.or.diagnosis.has.the.advantage.that.the.results.become.available.at.the.time.o.the.clinic.visit
Presumptive clinical diagnosis o HIV inection
No.single.clinical.diagnostic.algorithm.has.proved.highly.sensitive.or.specic.or.the.diagnosis.o.HIV.inection.Clinical.algorithms.are.rarely.more.than.70%.sensitive.or.the.accurate.diagnosis.o.inection.[37].and.they.vary.considerably.with.age,.and.in.particular.they.are.less.reliable.in.children.aged.under.12.months.[38].HIV.antibody.testing,.especially.rapid.testing,.and.increased.access.to.early.virological.testing.must.be.made.available.to.help.clinicians.implement.improved.diagnostic.algorithms.However,.there.are.situations.where.the.use.o.a.clinical.algorithm.may.be.required.to.initiate.appropriate.lie-saving.treatment.o.a.seriously.ill.child.under.the.age.o.18.months.Currently,.insucient.data.are.available.to.make.rm.recommendations.on.the.use.o.clinical.algorithms.combined.with.the.measurement.o.CD4.or.other.parameters.or.establishing.
HIV.inection.It.should.be.emphasized.that.WHO.clinical.staging.o.HIV.disease.can.only.be.employed.where.HIV.inection.has.been.established
Children aged under 8 months
For.inants.and.children.aged.under.18.months.where.access.to.virological.testing.is.not.yet.available.but.where.there.are.symptoms.suggestive.o.HIV.inection,.accompanied.by.positive.HIV.antibody.testing,.a.presumptive.clinical.diagnosis.o.severe.HIV.inection.may.be.necessary.in.order.to.permit.decision-making.on.the.need.or.the.initiation.o.potentially.lie-saving.ART.(see.Section.V).
WHO.encourages.researchers.and.national.programmes.to.validate.approaches.to.presumptive.
clinical.diagnosis.in.children.under.18.months.o.age,.including.studies.to.determine.i.%.CD4.or.CD4/CD8.ratio.combined.with.clinical.signs.and.symptoms.improves.the.early.diagnosis.o.HIV.inection. WHO. urges. national. programmes. to. increase. access. to. diagnostic. testing. or. HIV.inection. or. all. children. born. to. HIV-inected. women. The. development. o. tests. applicable. to.resource-limited.settings.so.as.to.allow.early.diagnosis.o.HIV.inection.in.inants.is.critical.to.the.implementation.o.recommendations.or.the.initiation.o.appropriate.care,.including.ART,.in.children.aged.under.18.months.
Children aged 8 months and more
For. children. aged. 18. months. and. older. with. signs. and. symptoms. suggestive. o. HIV,. WHO.strongly.recommends.the.use.o.antibody.testing.ollowing.national.protocols.in.order.to.diagnose.HIV.inection.(Table.2.&.Fig.1).Presumptive.clinical.diagnosis.o.severe.HIV.disease.is.thereore.not.indicated.because.standard.HIV.antibody.testing.is.diagnostic.o.HIV.inection.in.this.age.group. Some. clinical. conditions. are. very. unusual. without. HIV. inection. (ie. Pneumocystis.
7/30/2019 Anti Retroviral Therapy guidelines
15/152
pneumonia,.oesophageal.candidiasis,.lymphoid.interstitial.pneumonitis,.Kaposis.sarcoma.and.
cryptococcal.meningitis),.and.the.diagnosis.o.these.conditions.thus.suggests.HIV.inection.and.indicates.the.need.to.perorm.HIV.antibody.testing.
Table.2.summarizes.the.recommended.methodologies.or.establishing.the.presence.o.HIV(i )
Table 2. Summary o recommendations on methods or establishing the
presence o HIV inection in inants and children
Method odiagnosis
Recommendations or use Strength orecommendation/
level o evidenceVirologicalmethods
To.diagnose.inection.in.inants.and.children.aged.under.18.months;.initial.testing.is.recommended.rom.6.weeks.o.age
HIV.DNA.[A(I)]
HIV.RNA.[A(I)]
U.p24.ag.[CII]
HIVantibodytesting
To.diagnose.HIV.inection.in.mother.or.identiy.HIV.exposure.o.inant.
A(I)
To.diagnose.HIV.inection.in.children.aged.18.
months.or.more.
A(I)
To.identiy.HIV-antibody.positive.children.aged.under.18.months.and.support.the.presumptive.clinical.diagnosis.o.severe.HIV.disease.(section.V)
A(IV).a
To.exclude.HIV.inection.where.HIV.antibody.negative.in.children.aged.under.18.months.who.are.HIV.exposed.and.never.breasted.
.A(I)
To.exclude.HIV.inection.where.HIV.antibody.negative.in.children.aged.under.18.months.who.are.HIV.exposed.and.discontinued.breasteeding.or.more.than.6.weeks.
A.(IV )
a. Children.aged.under.18.months.who.have.positive.HIV.antibody.tests.include.those.who.are.truly.HIV-inected.and.those.who.have.persisting.maternal.antibody.but.are.uninected.By.the.age.o.12.months.most.uninected.children.have.lost.maternal.antibody.and.positive.antibody.testing.at.this.time.usually.indicates.HIV.inection,.although.conrmatory.testing.at.18.months.is.recommended.
(i). WHO. Technical.and. operational. recommendations. are.available. at:. http://dataunaidsorg/Publications/IRC-pub02/JC602-HIVSurvGuidel_enpd.&.http://wwwwhoint/diagnostics_laboratory/publications/en/HIV_Report15pd.
7/30/2019 Anti Retroviral Therapy guidelines
16/152
0AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Figure . Establishing presence of HIV infection in HIV exposed children aged under
8 months in resource-limited settings to facilitate ART and HIV care
a. The.risk.o.HIV.transmission.remains.i.breasteeding.continues.beyond.18.months.o.age.b. Inants.over.9.months.o.age.can.be.tested.initially.with.HIV.antibody.test,.as.those.who.are.HIV.Ab.negative.are.not.usually.HIV.
inected,.although.still.at.risk.o.acquiring.inection.i.still.breasteeding.
c. In.children.older.than.18.months.antibody.testing.is.denitived. Usually.HIV.antibody.testing.rom.9-18.months.o.agee. Where.virological.testing.is.not.readily.available.HIV.antibody.testing. should.be.perormed,.it. may.be.necessary. to.make.a.
presumptive.clinical.diagnosis.o.severe.HIV.disease.in.HIV.seropositive.children.(see.Box.1).Conrmation.o.diagnosis.should.be.sought.as.soon.as.possible
Non breastfed child Breastfed child
Diagnostic virological test from 6 weeks of age
Positive test result Negative test resultNegative test result
Child is uninfected Child is infected Child remains at risk ofacquiring HIV infection
until complete cessationof breastfeeding
a
Refer for HIV treatment andcare including initiation of ART
Child develops signs or symptoms suggestive of HIV Child remains well
Diagnostic HIV testingb,c
Routine follow-uptesting as per national
programmerecommendationsd
Virological test notreadily available
HIV antibody test eVirological test positive
HIV antibody positive andPresumptive severe HIV disease
Refer for assessment for HIV treatment and care including initiation of ART
Child is infected
Virological test availableNon.breased.
Breasted
7/30/2019 Anti Retroviral Therapy guidelines
17/152
The. decision-making. process. or. initiating. ART. in.inants.and. children. relies. on. clinical. and.
immunological. assessment. In. order. to. acilitate. scale-up. to. universal. access. to. ART,. WHO.emphasizes.the.importance.o.clinical.parameters.This.approach.aims.at.enabling.all.children.needing.treatment.to.receive.it,.even.i.the.diagnosis.o.HIV.is.presumptive.and.i.CD4.is.not.available. However,. where. possible,. using. the. results. o. CD4. measurement. is. valuable,.particularly. or. decisions. about. starting. therapy. in. less. sick. children,. and. WHO.encourages.national.programmes.to.increase.access.to.CD4.measurement.technologies.Decision-making.about.starting.treatment.is.particularly.important.or.children.aged.under.12.months.as.the.probability.o.death.in.untreated.HIV-inected.children.is.high:.mortality.rates.o.up.to.40%.by.the.age.o.1.year.have.been.reported.(2,3,39,40).
The.decision.about.when.to.start.ART.should.also.involve.evaluation.o.the.social.environment.o.the.child.who.may.need.therapy.This.should.include.the.identication.o.a.clearly.dened.caregiver.who.understands.the.prognosis.o.HIV.and.the.implications.o.ART.(ie.lielong.therapy,.non-adherence,.administration,.toxicities.and. storage.o. drugs).Access.to.nutritional.support.(see.Section.XIII).and.amily.support.groups,.preerably.including.the.identication.o.a.secondary.(back-up).inormed.caregiver.is.advised.The.status.o.disclosure.to.the.child.and.among.the.amily.are.also.important.when.making.decisions.about.the.initiation.o.ART
Clinical assessment o HIV-inected children
The.WHO.Paediatric.Clinical.Classication.o.HIV-related.disease.has.recently.been.revised.and.is.now.harmonized.with.the.adult.classication.system.(Table.3)
Table 3. WHO classication o HIV-associated clinical diseasea
Classication o HIV-associated clinical disease WHO clinical stage
Asymptomatic 1
Mild 2
Advanced 3
Severe 4
a. Annex.B.provides.urther.details.on.staging.events.and.criteria.or.recognizing.them
Clinical. staging. is. or. use. where. HIV. inection. has. been. conrmed. (ie. serological. and/or.virological.evidence.o.HIV.inection).It.is.inormative.or.assessment.at.baseline.or.entry.into.HIV.care.and.can.also.be.used.to.guide.decisions.on.when.to.start.CPT.in.HIV-inected.children.and.other. HIV-related. interventions,. including. when. to. start,. switch. or. stop. ART. in. HIV-inected.children,.particularly.in.situations.where.CD4.is.not.available.Annex.B.provides.urther.details.o.
the.specic.staging.events.and.the.criteria.or.recognizing.them
A. preliminary. analysis. o. the. revised. WHO. staging. based. on. clinical. signs. at. baseline. and.disease.history.in.children.enrolled.in.the.Children.with.HIV.Antibiotic.Prophylaxis.(CHAP).trial.
V. WHEN TO START ANTIRETROVIRAL THERAPYIN INFANTS AND CHILDREN
7/30/2019 Anti Retroviral Therapy guidelines
18/152
2AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
(41).showed.that.clinical.stage.without.ART.can.predict.mortality.However,.this.was.dependent.
on.the.malnutrition.criteria.in.the.staging.denitions.(D.Gibb,.unpublished.observations,.2005).The.clinical.stage.thereore.indicates.the.urgency.with.which.to.start.ART. (Table.4).Treatment.with.a.potent.and.ecient.ARV.regimen.improves.clinical.status.and.eectively.reverses.the.clinical.stage.There.is.an.urgent.need.or.studies.on.the.use.o.clinical.criteria.(ie.clinical.staging.events.on.treatment).or.when.to.switch.the.ARV.regimen.in.the.absence.o.viral.load.testing.(see.Section.X).
Immunological assessment o HIV-inected children
It.is.also.possible.to.measure.the.immunological.parameters.o.the.HIV-inected.child.and.assess.the.severity.o.HIV-related.immunodeciency.in.order.to.guide.decision-making.on.the.initiation.o.ART.The.results.o.CD4.measurement.should.be.used.in.conjunction.with.clinical.assessment.The.CD4.and.the.total.lymphocyte.count.(TLC).in.healthy.inants.who.are.not.inected.with.HIV.are.considerably.higher.than.those.observed.in.uninected.adults.and.slowly.decline.to.adult.values.by.the.age.o.about.6.years;.percentage.CD4+.(ie.%CD4+).values.vary.less.with.age.In.considering.the.results.o.immunological.parameters,.age.must.thereore.be.taken.into.account.as.a.variable.In.children.under.5.years.o.age.the.absolute.CD4.count.tends.to.vary.within.an.individual.child.more.than.%CD4+.Currently,.thereore,.the.measurement.o.%CD4+.is.thought.to. be.more.valuable. in.children. under.5. years.o. age.Absolute.CD4. counts.and,. to.a. lesser.
extent,.%CD4+.values,.fuctuate.within.an.individual.and.values.can.vary.with.intercurrent.illness,.physiological.changes,.timing.o.test.or.test.variability.Serial.measurements.are.thereore.more.inormative. than. individual. values. and. also. refect. trends. over. time. Where. possible,. these.assessments.should.compare.the.same.parameter;.ie.either.absolute.CD4.count.or.%CD4+.As. with. clinical. status,. immunological. recovery. occurs. with. successul. ART. Because. o. the.variability. o. both. absolute. CD4. counts. and. %CD4+,. two. values. below. threshold. should,. i.possible,. be. obtained. beore. the. initiation. o. ART. based. on. immunological. criteria. alone,.particularly.beore.starting.a.child.on.ART.with.no.or.mild.symptoms.o.HIV.(ie.clinical.stages.1.and.2).(5,.42-44).The.results.o.CD4.measurement.are.also.useul.or.monitoring.response.to.
treatmentThe.threshold.CD4.levels.or.severe.immunodeciency.(ie.
7/30/2019 Anti Retroviral Therapy guidelines
19/152
3
mm3.or.inants.aged.
7/30/2019 Anti Retroviral Therapy guidelines
20/152
4AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Table 4. Recommendations or initiating ART in HIV-inected inants and children
according to clinical stage and availability o immunological markers
WHOpaediatric
stage
Availabilityo CD4 cell
measurements
Age-specic treatment recommendation
[A (II)]*
2 months
4a CD4 bTreat.all
No.CD4
3a CD4 b Treat.all Treat.all,.CD4-guided.in.those.children.
with.TB,c.LIP,.OHL,.thrombocytopenia
No.CD4 Treat.allc
2 CD4 b CD4-guidedd
No.CD4 TLC- guided d
1 CD4b
CD4-guidedd
No.CD4b Do.not.treat
*. Strength.o.recommendation/level.o.evidencea. Stabilize.any.opportunistic.inection.beore.initiation.o.ARTb. Baseline.CD4.is.useul.or.monitoring.ART.even.i.it.is.not.required.to.initiate.ARTc. In.children.with.pulmonary.or.lymph.node.tuberculosis.the.CD4.level.and.clinical.status.should.be.used.to.determine.the.need.or.
and.timing.o.initiation.o.ART.in.relation.to.tuberculosis.treatment.(see.Section.XII)d. Reer.to.Table.5.or.CD4.and.table.6.or.TLC.values
Table . CD4 criteria or severe HIV immunodeciency
Immunologicalmarkera
Age-specic recommendation to initiate ART b[A (I)]*
years
%CD4+c
7/30/2019 Anti Retroviral Therapy guidelines
21/152
Table . TLC criteria or severe HIV immunodeciency requiring initiation o
ART; suggested or use in inants and children with clinical stage 2and where CD4 measurement is not available
Immunologicalmarkera
Age-specic recommendation to initiate ART b[C (II)]*
7/30/2019 Anti Retroviral Therapy guidelines
22/152
AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Box.1.lists.the.criteria.or.the.presumptive.clinical.diagnosis.and.Box.2.summarizes.the.WHO.
recommendations.or.starting.ART.in.inants.and.children
Box . Criteria or presumptive diagnosis o severe HIV disease in inants and
children aged under 8 months in situations where virological testing
is not available
[B (IV)]*
A.presumptive.diagnosis.o.severe.HIV.disease.should.be.made.i :. the.inant.is.conrmed.as.being.HIV.antibody-positive.
and
. diagnosis.o.any.AIDS-indicator.condition(s)a.can.be.made..or
. the.inant.is.symptomatic.with.two.or.more.o.the.ollowing:.. oral.thrush;b
. severe.pneumonia;b
. severe.sepsisbOther.actors.that.support.the.diagnosis.o.severe.HIV.disease.in.an.HIV-seropositive.inant.include:
. recent.HIV-related.maternal.death.or.advanced.HIV.disease.in.the.mother;.. %CD4+.
7/30/2019 Anti Retroviral Therapy guidelines
23/152
Box 2. Summary o WHO recommendations or ART initiation in inants and
children
1. Inants.and.children.with.established.HIV.inection.(as.per.Section.IV).should.be.started.on.ART.i.they.have:.
. WHO.paediatric.clinical.stage.4.disease.(irrespective.o.CD4);
. WHO.paediatric.clinical.stage.3.disease.(irrespective.o.CD4,.although.it.may.add.guidance);.or.children.aged.over.12.months.with.tuberculosis,.lymphocytic.interstitial.pneumonia,.oral.hairy.leukoplakia.or.thrombocytopaenia,.ART.initiation.
may.be.delayed.i.CD4.is.available.and.above.threshold.valuesa.or.initiating.ART;.
. WHO.paediatric.clinical.stage.2.disease.and.CD4.or.TLCb.value.at.or.below.threshold;a
. WHO.paediatric.clinical.stage.1.disease.and.CD4.value.at.or.below.thresholda.
2. I.virological.testing.is.not.available.to.conrm.HIV.inection,.HIV.antibody-positive.inants.and.children.aged.under.18.months.should.be.considered.or.ART.i.they.have.clinically.diagnosed.presumed.severe.HIV.diseasec.
a. Threshold.values.or.CD4.are.provided.in.Table.5
b. Threshold.values.or.TLC.are.provided.in.Table.6.TLC.is.useul.or.decision-making.or.o.inants.and.children.with.clinical.stage.2.and.should.only.be.considered.where.CD4.measurement.is.not.available
c. Criteria.or.clinical.diagnosis.o.presumptive.severe.HIV.disease.are.provided.in.Box.1
7/30/2019 Anti Retroviral Therapy guidelines
24/152
8AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Considerations or treatment using a public health approach
Countries.are.encouraged.to.use.a.public.health.approach.to.support.and.acilitate.wider.access.to.ART.Among.the.key.tenets.o.this.approach.are.standardization.and.simplication.o.ARV.regimens.It.is.thereore.suggested.that.countries.select.a.limited.number.o.rst-line.regimens.and.suitable.second-line.regimens,.recognizing.that.individuals.who.cannot.tolerate.or.ail.the.rst-line.and.second-line.regimens.may.require.input.rom.more.experienced.physicians.The.use.o.three.ARV.medications.is.currently.the.standard.treatment.or.HIV.inection.in.order.to.achieve.the.best.possible.suppression.o.viral.replication.and.to.arrest.the.progression.o.HIV.disease. It. is. important. to. maximize. the. durability. and. ecacy. o. any. rst-line. regimen. by.
incorporating.approaches.to.support.adherence.When.appropriate.ARV.regimens.are.being.selected.or.the.national.ormulary,.programme-level.actors.should.be.taken.into.consideration.These.include:.
. ability.to.treat.all.ages;
. suitability. o.drug. ormulation,. particularly. or. inants. and. young.children.and. caregivers,.including,.where.possible,.licensing.approval.by.national.drug.regulatory.authorities.or.the.product.and.the.recommended.dose;
. toxicity.prole,.including.teratogenicity;.
. laboratory.monitoring.requirements;
. potential.or.maintenance.o.uture.treatment.options;.
. anticipated.patient.adherence.(including.consideration.o.drug.regimens.taken.by.parents.or.caregivers,.as.appropriate);.
. prevalent.coexisting.conditions.(eg.coinections,.malnutrition,.malaria,.TB,.possibly.hepatitis.B.and.C);.
. availability.and.cost-eectiveness;
. capacity.o.drug.procurement.and.supply.systems
The.choice.o.an.appropriate.ARV.regimen.may.be.urther.infuenced.by:.access.to.a.limited.number.o.ARV.drugs.in.orms.suitable.or.the.treatment.o.inants.and.young.children.(see.special.considerations.below);.limited.health.service.inrastructures.(including.human.resources);.and.the.presence.o.varied.HIV.types.(eg.HIV-2)
VI. WHAT TO START RECOmmENDED FIRST-LINE ARVREGImENS IN INFANTS AND CHILDREN
7/30/2019 Anti Retroviral Therapy guidelines
25/152
Considerations or drug ormulations and doses or children
Quality-assured(i).ARV.drugs.in.xed-dose.combinations.(FDCs),(ii).or.blister.packs(iii).are.mostly.used.in.adults.and.older.children.It.is.to.be.hoped.that.they.increasingly.become.available.in.the.uture.or.administration.to.younger.children.Once-daily.dosing.has.become.available.or.some.adult. ARV. combinations. and. urther. simplies. drug. regimens. The.advantages. o.FDCs.and.once-daily. dosing.include. improved. adherence. which,.in. turn,. limits. the.emergence. o. drug.resistance.and.simplies.ARV.storage.and.distribution.logistics.
WHO strongly encourages the development o ormulations appropriate or paediatric use,
particularly solid ormulations (e.g. crushable, dispersible, granular, scored tablets or capsules
that can be opened) in doses that can be used by paediatric patients under 14 kg.
Syrups.and.solutions.remain.necessary.or.treating.inants.and.very.young.children.who.cannot.swallow. whole. tablets. or. capsules. but. they. have. shortcomings,. which. may. include. limited.availability,.high.cost,.storage.diculties,.reduced.shel-lie,.alcohol.excipient.and.poor.palatability.As. children. become. older. it. is. preerred. to. give. solid. ormulations. (par ts. o. scored. tablets. or.combination.preparations;.see.WHO/UNICEF.meeting.report.on.paediatric.ARV.ormulations.at.
http://wwwwhoint/3by5/paediatric/en/indexhtml). For. some. ARVs,. capsules. and. tablets. are.available.in.suciently.low.doses.to.enable.accurate.dosing.or.children.The.pharmacokinetics.o.some.crushed.tablets.or.sprinkled.capsule.contents.have.been.evaluated.However,.many.drugs.do.not.have.solid.ormulations.in.doses.appropriate.or.paediatric.use,.and.some.solid.ormulations.do. not. have. all. the. drug. components. evenly. distributed. in. the. tablets,. while. others. lack.pharmacokinetic. data. to. enable. accurate. dosing. National. drug. regulatory. authorities. should.consider.these.actors.when.making.decisions.on.licensing.products.or.use.in.children.
While.satisactory.virological.and.immunological.benets.in.children.receiving.an.adult.xed-dose.combination.o.stavudine/lamivudine/nevirapine.(d4T/3TC/NVP).tablets.in.ractions.were.reported.
rom.Thailand.(48).and.Uganda.(49),.the.use.o.tablets.that.require.cutting.up,.particularly.unscored.tablets,.can.result.in.the.underdosing.or.overdosing.o.children,.and.this.may.lead.to.an.increased.risk.o.resistance.or.toxicity.Moreover,.the.doses.cannot.easily.be.adjusted.as.the.children.grow,.which.may.urther.contribute.to.underdosing.The.splitting.o.adult-dose.solid.ormulation.ARVs,.while.suboptimal,.may,.however,.be.the.only.currently.available.option.or.the.treatment.o.children.as.soon.as.easible.(usually.when.a.weight.o.1012.kg.is.achieved),.and.may.be.considered.when.no.alternatives.are.available.The.use.o.tablet.cutters.is.benecial.but.it.is.preerable.not.to.cut.tablets.to.ractions.below.a.hal.Pharmacokinetic.studies.in.Malawian.children.conrm.that.the.use.o.single-drug.liquid.ormulations.is.better.than.splitting.adult.FDCs.or.smaller.children.(50).
(i). In.the.context.o. this. document,.quality-assured. medicines.assembled. in.xed-dose.combinations. (FDCs). include.individual.products.deemed.to.meet.international.standards.or. quality,.saety.and.ecacy.For.WHOs.work.on.the.prequalication.o.ARVs,.see:.http://wwwwhoint/3by5/amds/en/
(ii). FDCs.include.two.or.more.active.pharmacological.produ cts.in.the.same.pill,.capsule,.granules,.tablet.or.solution
(iii). A.blister.pack.is.a.plastic.or.aluminium.blister.containing.two.or.more.pills,.capsules.or.tablets
7/30/2019 Anti Retroviral Therapy guidelines
26/152
20AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Dosing.in.children.is.usually.based.on.either.body.surace.area.or.weight.(51).As.these.change.
with. growth,. drug. doses. must. be. adjusted. in. order. to. avoid. the. risk. o. underdosage.Standardization.is.important.and.it.is.desirable.to.provide.health.care.workers.with.tables.o.simplied.drug. doses. that. can.be. administered. Such. tables.may. vary.between.localities. in.accordance.with.the.availability.o.ARV.drugs.and.ormulations.in.the.countries.concerned.WHO.has.developed.prototype.dosing.tables.based.on.weight,.and.tools.to.assist.countries.with.the.standardization.and.calculation.o.drug.doses (i )(Annex.E).Fixed-dose.ormulations.or.children.became.available.in.late.2005;.they.include.d4T/3TC/NVP.in.dierent.strengths
FDC o standard frst and second line ARV regimens are urgently needed or younger children.
Considerations or the choice o a rst-line regimen
Studies.o.antiretroviral.therapy.in.children.demonstrate.that.similar.improvements.to.those.obtained.in.adults.are.seen.in.morbidity,.mortality.and.surrogate.markers.with.many.dierent.potent.ARV.regimens.(39,.52-55).The.preerred.option.when.choosing.a.rst-line.regimen.or.inants.and.children.is.two.nucleoside. reverse. transcriptase. inhibitors. (NRTIs). plus. one. non-nucleoside. reverse. transcriptase.inhibitor.(NNRTI).(Box.3).These.drugs.prevent.HIV.replication.by.inhibition.o.the.action.o.reverse.
transcriptase,.the.enzyme.that.HIV.uses.to.make.a.DNA.copy.o.its.RNA.The.technical.reerence.group.based.this.decision.on.available.evidence,.clinical.experience.and.programmatic.easibility.or.the.wider. introduction. o. ART. to. inants. and. children. in. resource-limited. settings. NRTI/NNRTI-based.regimens.are.ecacious.and.generally.less.expensive;.generic.ormulations.are.more.oten.available.and.a.cold.chain.is.not.required.In.addition,.they.preserve.a.potent.new.class.(ie.protease.inhibitors.[PIs]).or.the.second.line.The.disadvantages.include.dierent.hal-lives,.the.act.that.a.single.mutation.is.associated.with.resistance.to.some.drugs.(eg.lamivudine.[3TC],.NNRTIs),.and,.in.respect.o.the.NNRTIs,.a.single.mutation.can.induce.resistance.to.all.currently.available.drugs.in.the.class.
Active.components. o. these. regimens. may. include. a. thymidine.analogue. NRTI. (ie.stavudine.
[d4T],.zidovudine.[AZT]).or.a.guanosine.analogue.NRTI.(ie.abacavir.[ABC]),.combined.with.a.cytidine. analogue. NRTI,. (ie. lamivudine. [3TC]. or. emtricitabine. [FTC]). and. an. NNRTI. (ie.eavirenz.[EFV].or.nevirapine.[NVP]).A.caveat.is.that.EFV.is.not.currently.recommended.or.use.in.children.under.3.years.o.age.because.o.a.lack.o.appropriate.dosing.inormation,.although.these. matters. are. under. study. For. such. children,. consequently,. NVP. is. the. recommended.NNRTI.Additional.concerns.about.NNRTIs.as.components.o.rst-line.regimens.relate.to.their.use.in.adolescents.(see.Section.XIV);.these.include.the.teratogenic.potential.o.EFV.in.the.rst.trimester.o.pregnancy.and.the.hepatotoxicity.o.NVP.in.adolescent.girls.with.CD4.absolute.cell.counts.>250/mm3.The.available.data.on.inants.and.children.indicate.a.very. low.incidence.o.
severe.hepatotoxicity.or.NVP.without.association.with.CD4.count.(56)
(i). A.web-based.tool.to.assist.in.development.o.dosing.tables.or.national.programmes.is.available.on.the.WHO.website.http://wwwwhoint/paediatric/en/indexhtml
7/30/2019 Anti Retroviral Therapy guidelines
27/152
2
Box 3. Summary o recommended preerred rst-line ARV regimens or
inants and children
Regimen o 2 NRTI plus NNRTIa
[A.(II)]*
A Z T b.+.3TC c.+.NVP d/ EF V e
d4T b.+.3TC c.+.NVP d/E F V e
ABC.+.3TC c.+.NVP d/ EF Ve
*. Strength.o.recommendation/level.o.evidencea. The.use.o.AZT,.d4T,.ABC.with.3TC.results.in.several.possible.dual.nucleoside.combinations.(see.ollowing.section.on.choice.o.
NRTI)b. AZT.should.not.be.given.in.combination.with.d4T.c. Where.available,.FTC.can.be.used.instead.o.3TC.in.children.over.3.months.o.aged. NVP.should.be.used.with.caution.in.postpubertal.adolescent.girls.(considered.as.adults.or.treatment.purposes).with.baseline.
CD4.absolute.cell.counts.>250/mm3e. EFV.is.not.currently.recommended.or.children.under.3.years.o.age.and.should.be.avoided.in.postpubertal.adolescent.girls.who.
are.either.in.the.rst.trimester.o.pregnancy.or.are.sexually.active.and.not.receiving.adequate.contraception.
The.use.o.a.triple.NRTI.regimen.(ie.AZT/d4T.+.3TC.+.ABC).can.be.considered.as.an.option.or.
simpliying.initial.therapy.in.special.circumstances.(Box.4).A.concern.is.the.somewhat.lower.virological. potency. o. this. regimen. compared. to. a. two-class. triple. drug. combination. in. adult.studies.(57-60).and.thereore.its.use.is.currently.restricted.to.special.circumstances,.in.particular.or.inants.and.children.receiving.TB.treatment,.a.situation.where.NVP.may.not.be.an.optimal.choice.because.o.drug.interactions.with.riampicin.(see.Section.XII).Another.possible.indication.or.the.use.o.a.triple.NRTI.regimen.is.the.treatment.o.pregnant.adolescent.girls.with.CD4.absolute.cell.counts.>250/mm3.This.regimen,.especially.where.combined.in.a.single.pill,.could.also.be.considered.in.adolescents.with.anticipated.or.documented.poor.adherence.(see.Section.XIV).
Box 4. Recommended alternative ARV regimen or inants and children to
simpliy management o toxicity, comorbidity and drug-drug interaction
Regimen o triple NRTI
[C.(III)]*
AZT/d4Ta.+.3TCb.+.ABC
*. Strength.o.recommendation/level.o.evidencea. AZT.should.not.be.given.in.combination.with.d4Tb. Where.available,.FTC.can.be.used.instead.o.3TC.in.children.over.3.months.o.age
7/30/2019 Anti Retroviral Therapy guidelines
28/152
22AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Choice o NRTIs
The.drugs.rom.the.NRTI.class.recommended.or.children.within.the.public.health.approach.are.described.below
Lamivudine (3TC),.is.a.potent.NRTI.with.an.excellent.record.o.ecacy,.saety.and.tolerability.in.HIV-inected.children.and.is.a.core.component.o.the.dual.NRTI.backbone.o.therapy.It.is.usually.given.twice.daily.in.children.and.has.been.incorporated.into.a.number.o.FDCs.
Emtricitabine (FTC).is.a.newer.NRTI.that.has.recently.been.included.in.WHOs.recommended.rst-line. regimens. or. adults. as. an. option. and. is. also. available. or. use. in. children. FTC. is.
structurally.related.to.3TC.and.shares.its.resistance.prole.(61).Where.available.it.can.be.used.in.children.over.3.months.o.age.as.an.alternative.to.3TC
The.choice.between.d4T,.AZT.or.ABC.to.be.combined.with.3TC.should.be.made.at.the.country.level.on.the.basis.o.local.considerations.but.it.is.recommended.that.at.least.two.o.these.NRTIs.be.available.to.allow.the.substitution.o.one.drug.or.the.other.should.there.be.toxicity.
Stavudine (d4T). is. an. NRTI. that. is. initially. better. tolerated. than. AZT. and. does. not. require.haemoglobin.or.laboratory.monitoring.However,.among.the.NRTIs.it.has.been.consistently.most.associated.with.lipoatrophy.(62).and.lactic.acidosis.In.addition,.elevated.hepatic.transaminases.and. pancreatitis. have. been. observed. d4T. can. also. cause. peripheral. neuropathy,. although.
these.complications.appear.to.be.less.common.in.children.than.in.adults.(63,.64).d4T.liquid.ormulations.require.a.cold.chain.and.the.capsule.size.starts.at.15.mg.only.While.ewer.laboratory.monitoring. requirements.may.be.a. good.reason.to.avour. d4T. over. AZT. as.the.chosen. NRTI.component,.in. particular. during. the.rapid.scale-up. o. programmes,. the. considerable. risk. o.lipoatrophy. in. children. treated. with. d4T-containing. regimens. remains. National. programmes.may.thereore.need.to.take.into.account.the.comparative.short-term.and.long-term.toxicities.o.rst-line.options.(see.Section.VIII).and.introduce.measures.or.the.close.monitoring.o.drugs.associated.with.an.increased.risk.or.toxicities.It.is.worth.emphasizing.that.d4T.and.AZT.should.never.be.used.together.because.o.proven.antagonism.between.them.(65,.66).(Box.5).
Zidovudine (AZT).is.generally.well.tolerated.in.children.but.has.been.associated.with.metabolic.complications.o.therapy,.although.to.a.lesser.extent.than.d4T.Initial.drug-related.side-eects.are. more. requent. with. AZT. and. the. drug. can. cause. severe. anaemia. and. neutropenia;.haemoglobin.monitoring.beore.and.during.treatment.with.AZT.is.thus.useul.This.is.particularly.important.in.areas.with.stable.malaria.or.where.malnutrition.is.common.and.anaemia.is.highly.prevalent.in.young.children.Large.volumes.o.AZT.liquid.ormulation.are.oten.poorly.tolerated.d4T.can.be.substituted.or.AZT.in.the.event.o.intolerance.to.the.latter.and.vice.versa,.except.in.cases.o.suspected.lactic.acidosis,.where.neither.drug.should.be.restarted.As.noted.above,.AZT.should.not.be.administered.in.combination.with.d4T
Abacavir (ABC),.has.been.included.in.these.revised.paediatric.guidelines.as.an.alternative.NRTI.in.rst-line.therapy,.representing.a.change.rom.the.2003.guidelines.that.recommended.reserving.the.use.o.ABC.as.part.o.second-line.regimens.Clinical.trial.results.in.antiretroviral-naive.persons.demonstrating.ecacy,.availability.o.ABC.in.paediatric.ormulation,.and.the.resulting.potential.to.
7/30/2019 Anti Retroviral Therapy guidelines
29/152
23
deliver. amily-based. care. o.HIV-inected. parents. and.children. with. ABC/3TC,. oset. concerns.
about.introducing.an.additional.rst-line.drug.Reports.rom.a.randomized,.partly.blind.multicentre.trial.comparing.dual.NRTI.regimens.(PENTA-5).(67).have.shown.that.ABC-containing.dual.NRTI.regimens.(ABC/3TC.or.ABC/AZT).are.more.eective.than.regimens.containing.AZT.+.3TC.in.children.with.HIV-1.who.have.not.been.previously.treated.The.results.have.also.suggested.a.similar.saety.prole.in.children.to.that.in.adults,.with.very.little.haematological.toxicity.NRTI.combinations.containing.ABC.thereore.provide.a.good.NRTI.backbone.or.use.with.NNRTIs.or.as.part.o.a.triple.nucleoside.regimen.O.all.the.NRTI.drugs,.ABC.has.the.least.eect.on.mitochondrial.DNA.(68).and.would.be.the.preerred.substitute.or.d4T.in.children.developing.lactic.acidosis.while.receiving.a.d4T-containing. regimen. ABC. could. also. be. substituted. or. AZT. in. the. event. o. intolerance.
However,.ABC.is.associated.with.a.potentially.atal.hypersensitivity.reaction.in.about.3%.o.children.who.receive.it.(67).In.inants.and.children.suspected.o.having.a.hypersensitivity.reaction,.ABC.should.be.stopped.and.not.restarted.(see.Section.VIII).Children.and/or.their.caregivers.should.be.advised.about.the.risk.o.this.serious.hypersensitivity.reaction.and.the.need.to.consult.their.care.provider.immediately.i.signs.or.symptoms.o.a.hypersensitivity.reaction.occur.
Tenoovir (TDF),.is.another.drug.that.has.been.incorporated.as.an.eective.option.or.rst-line.regimens.in.adults.Because.o.concerns.about.the.limited.data.on.saety.and.toxicity.(ie.bone.mineralization.and.potential.renal.toxicity).the.use.o.TDF.in.children.is.not.encouraged.until.urther.data.become.available.TDF.is.generally.well.tolerated.(69),.although.there.have.been.
reports.o.renal.insuciency.in.adult.patients.receiving.it.(70-72).A.study.in.16.HIV-inected.children.(age.range.64.to.179.years).on.12-month.treatment.comparing.TDF.and.d4T.reported.that. TDF. did. not. impair. bone. mineral. accrual. while. demonstrating. a. good. immunological.response. to. ART. (73). However,. a. paediatric. study. in. HIV-inected. antiretroviral-experienced.children.(age.range.83.to.162.years).demonstrated.a.decrease.o.more.than.6%.in.bone.mineral.density.in.about.30%.o.those.evaluated.ater.48.weeks.o.TDF.therapy,.thus.potentially.limiting.the.use.o.TDF.among.prepubertal.children.(74).
Didanosine (ddI).is.an.adenosine.nucleoside.analogue.NRTI.Its.use.is.usually.reserved.or.second-line.regimens.(see.Section.XI).
7/30/2019 Anti Retroviral Therapy guidelines
30/152
24AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Box.5.Summarizes.the.NRTI.drug.combinations.that.should.be.avoided.
Box . NRTI drug combinations to be avoideda
. d4T.+.AZT.-.both.drugs.work.through.common.metabolic.pathways.[A(I)]*
.d4T.+.ddIb.-.these.drugs.have.overlapping.toxicities.[A(I)]*.TDF.+.3TC.+.ABCc.
.TDF.+.3TC.+.ddId.
.TDF.+.ddI.+.NNRTIe
these.regimens.are.associated.with.a.high.incidence.o.early.virologic.ailure.[A(III)].*
*. Strength.o.recommendation/level.o.evidencea. Based.on.data.rom.studies.perormed.in.adultsb. Didanosine.(ddI).is.an.adenosine.analogue.NRTI.which.is.generally.reserved.or.second-line.regimens.(see.Section.XI).c. Data.rom.three.clinical.trials.in.adults.involving.the.combination.o.TDF.+.3TC.+.ABC.demonstrated.high.rates.o.virological.
ailure.and.drug.resistance.Given.these.concerns.and.the.lack.o.clinical.data,.this.NRTI.backbone.should.not.be.used.in.treatment-nave.patients.Another.report.conrms.that.ABC.and.TDF.select.or.the.K65R.mutation,.which.reduces.susceptibility.to.both.drugs.(75).
d. A.pilot.study.using.this.regimen.resulted.in.a.high.incidence.o.K65R.mutation.and.virologic.ailure.(76).e. Source:.reerences.(77-80)
Choice o NNRTIs
NNRTI-based.regimens.are.now.the.most.widely.prescribed.combinations.or.initial.therapy.They.are.potent,.ie.they.rapidly.reduce.the.viral.load,.but.are.inactive.with.respect.to.HIV-2.and.group.O.o.HIV-1,.and.a.single.mutation.can.induce.cross-class.resistance.The.NNRTIs.eavirenz.(EFV). and. nevirapine. (NVP). have. both. demonstrated. clinical. ecacy. when. administered. in.appropriate. combination. regimens. in. children. However,. dierences. in. toxicity. prole,. the.potential. or. interaction. with. other. treatments,. a. lack. o.dosing. inormation. or. EFV. in.young.children,.and.cost.are.actors.that.need.to.be.taken.into.consideration.when.choosing.an.NNRTI.(81-88)
Eavirenz (EFV).is.not.currently.recommended.or.use.in.inants.and.children.under.3.years.o.age.because.there.is.no.established.dosing.EFV.is.primarily.associated.with.toxicities.related.to.the.central.nervous.system.(CNS),.teratogenicity.and.rash.Rash.is.more.requent.in.children.than.adults,. is. generally. mild,. and. usually. does. not. require. discontinuation. o. therapy. The. CNS.symptoms.typically.abate.ater.10.to.14.days.in.the.majority.o.patients;.observational.studies.have.revealed.transient.CNS.disturbance.in.26%.to.36%.o.children.receiving.EFV.(55,.88).EFV.should.be.avoided.in.children.with.a.history.o.severe.psychiatric.illness,.where.there.is.a.potential.or.pregnancy.(unless.eective.contraception.can.be.assured).and.during.the.rst.trimester.o.pregnancy.In.these.situations,.NVP.may.be.the.better.choice.(see.below).EFV.may.be.considered.as.the.NNRTI.o.choice.in.children.with.TB/HIV.coinection.(see.Section.XII)
Nevirapine (NVP).should.only.be.given.in.combination.with.other.antiretrovirals,.except.when.used.or.single-dose.prophylaxis.to.reduce.the.risk.o.perinatal.HIV.transmission.NVP.has.a.higher.incidence.o.rash.than.other.ARVs.NVP-related.rash.may.be.severe.and.lie-threatening,.including.Stevens-Johnson.syndrome,.and,.as.noted.above,.NVP.is.also.associated.with.a.rare.
7/30/2019 Anti Retroviral Therapy guidelines
31/152
2
but. potentially. l ie-threatening. risk. o. hepatotoxicity. In. these. situations,. NVP. should. be.
permanently.discontinued.and.not.restarted.(see.Sections.VIII.and.IX).This.makes.the.drug.less.suitable.or.treating.children.who.use.other.hepatotoxic.medications,.or.drugs.that.can. cause.rash,.or.both,.such.as.riampicin.or.the.treatment.otuberculosis.There.are.limited.data.on.the.use.o.NVP.in.children.coinected.with.HIV.and.hepatitis.B.NVP.is.currently.the.only.NNRTI.syrup.available. or. inants. It.also.exists.as.part. o.three-drug. FDCs. which.could.be. used.or. older.children.when.quality-assured.ormulations.o.proven.bioequivalence.are.available
NVP.may.be.the.preerred.choice.in.adolescent.girls.when.there.is.potential.or.pregnancy,.or.during.the.rst.trimester. o.pregnancy. when. EFV.should. be.avoided.because. o.its.potential.teratogenic.eect.However,.symptomatic.NVP-associated.hepatotoxicity.or.serious.rash,.while.
uncommon,.is.more.requent.in.women.than.in.men,.and.is.more.likely.to.be.seen.in.antiretroviral-naive.women.with.higher.CD4.cell.counts.(>250.cells/mm 3).Thus,.NVP.should.be.used.with.caution.in.adolescent.girls.with.CD4.counts.between.250.and.350.cells/mm 3;.i.used.in.such.adolescent.girls,.careul.monitoring.is.needed.during.the.rst.12.weeks.o.therapy,.preerably.including.liver.enzyme.monitoring.
Limited.data.indicate.that.both.EFV.and.NVP.may.interact.with.estrogen-based.contraceptive.pills.Because.exposure.to.EFV.should.be.avoided.in.the.rst.trimester.o.pregnancy.it.is.recommended.that. sexually. active. adolescent. girls. receiving. EFV. consistently. use. barrier. methods. to. prevent.pregnancy. in. addition. to. or. instead. o. oral. contraceptives. Studies. are. in. progress. to. evaluate.
interactions.between.medroxyprogesterone.acetate.and.selected.PI.and.NNRTI.drugs.
Annex. E. provides. more. detailed. inormation. on. dosing,. preparations,. storage. and. special.instructions.on.the.administration.o.the.above-listed.drugs
Use o protease inhibitors (PIs) in initial therapy
It.is.recommended.that.the.PI.class.o.drugs.be.reserved.or.second-line.therapy.because.the.use.o.PIs.in.an.initial.treatment.regimen.compromises.any.subsequent.second-line.regimen.Until.urther.data.become.available,.this.also.holds.true.in.situations.where.single-dose.NVP.has.
been.used.or.PMTCT.(see.Section.VII).Currently.available.PIs.are.described.in.more.detail.in.Section.XI.
7/30/2019 Anti Retroviral Therapy guidelines
32/152
2AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
ART in inants exposed to ARVs through interventions
to prevent mother-to-child transmission
I.a.mother.has.received.ARVs.during.pregnancy,.either.or.prevention.o.transmission.o.the.virus.to.her.inant.or.or.her.own.disease,.there.is.a.possibility.that.the.inant.may.become.inected.with.drug-resistant.virus.Additionally,.resistance.could.be.induced.de.novo.in.an.inected.inant.who.is.exposed.to.an.ARV.drug.being.used.or.prevention.(ie.the.inant.component.o.MTCT).beore.the.inection.status.o.the.inant.is.known.This.is.a.particular.problem.i.NVP.or.3TC.has.been.used,.either.alone.or.as.a.component.o.a.two-drug.regimen,.or.prevention.o.MTCT,.because.a.single.point.mutation.is.associated.with.resistance.to.each.o.these.drugs.(89,.90).In.HIVNET.012,.
ollowing.single-dose.NVP,.46%.o.inected.inants.had.NNRTI-associated.mutations.(primarily.the.Y181C.mutation,.which.may.not.always.be.associated.with.cross-resistance.to.EFV ).As.has.been. observed. in. mothers,. these. mutations. ade. with. time. but. may. persist. as. minor. viral.subpopulations.(89).It.is.not.known.whether.ARV.choices.should.be.modied.or.inants.who.have.been.exposed.to.ARVs.used.or.PMTCT.Studies.in.children.are.in.progress.(ie.South.Arica.NEVEREST.study.and.Botswana).or.are.planned.(ie.multicountry.PACTG.1060),.as.they.are.in.mothers,.to.investigate.whether.single-dose.NVP.prophylaxis.compromises.subsequent.ART.with.NNRTI-based.regimens.WHO.recognizes.the.urgency.o.such.research.However,.until.there.are.data.allowing.these.questions.to.be.denitively.answered,.children.who.require.ART.and.who.have.previously.received.single-dose.NVP.or.3TC.as.part.o.PMTCT.should.be.considered.eligible.or.NNRTI-based.regimens.and.should.not.be.denied.access.to.lie-sustaining.therapy.
Ongoing exposure to ARVs due to maternal ART in breast eeding inants
The.penetration.o.ARVs.into.human.breast.milk.in.lactating.women.has.not.been.quantied.or.most.ARVs.Although.some.ARVs,.such.as.NVP,.AZT.and.3TC,.are.known.to.be.present.in.breast.milk,.the.concentration.and.quantity.o.drug.ingested.by.inants.would.be.less.than.those.needed.to.achieve.therapeutic.levels.(30,.81).Consequently,.i.a.breasteeding.inant.is.ill.enough.to.require. ART,. the. administration. o. ARVs. at. standard. paediatric. doses. should. be. initiated.
regardless.o.whether.the.mother.is.receiving.ART,.but.closer.monitoring.o.the.inant.or.potential.toxicity.should.be.considered.Because.o.the.benets.o.breastmilk,.continued.breasteeding.should.be.encouraged.In.addition,.it.is.possible.that.the.ingestion.o.subtherapeutic.levels.o.some.ARVs.by.breasteeding.inants.could.lead.to.the.development.o.drug.resistance.in.the.inants. virus,. diminishing. the. ecacy. o. the. prescribed. paediatric. regimen,. but. there. are.currently.insucient.data.to.make.recommendations.
Box.6.summarizes.the.recommendations.on.ART.in.inants.with.previous.or.continuing.exposure.to.ARVs.
VII. CONSIDERATIONS FOR ART IN INFANTS PREVIOUSLYExPOSED TO ARV DRUGS
7/30/2019 Anti Retroviral Therapy guidelines
33/152
2
Box . Summary o recommendations on ART in inants and children
exposed to ARV drugs [B (IV)]*
. Inants.who.were.exposed.to.ARVs.or.prevention.o.mother-to-child.transmission,.either.the.maternal.or.inant.component,.and/or.
. Breasteeding.inants.who.are.exposed.to.antiretroviral.drugs.because.o.maternal.
ART
should.be.considered.eligible.or.the.standard.2.NRTIs.+.1.NNRTI.rst-line.ARV.regimen.using.the.same.doses.and.criteria.as.are.outlined.in.Sections.V.and.VI
Research.is.urgently.needed.to.identiy.the.ecacy.o.ART.in.inants.with.previous.or.continuing.exposure.to.ARVs.
*. Strength.o.recommendat ions/.level.o.evidence
7/30/2019 Anti Retroviral Therapy guidelines
34/152
28AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
It.is.sometimes.dicult.to.dierentiate.between.complications.o.HIV.disease.and.toxicity.(also.
known.as.adverse.events).secondary.to.ARV.drugs.used.or.the.management.o.HIV.inection.or.drug-drug.interactions.Alternative.explanations.or.toxicity.must.be.excluded.beore.concluding.that.it.is.secondary.to.the.ARV.drugs.Such.explanations.or.an.observed.toxicity.could.include.a.concurrent.inectious.process.(eg.common.childhood.illnesses.including.hepatitis.A.virus.inection.in.a.child.with.symptoms.o.hepatitis,.or.malaria.in.a.child.with.severe.anaemia),.or.a.reaction.to.a.non-ARV.drug.that.is.being.given.concurrently.with.ARV.drugs.(such.as.isoniazid-induced.hepatitis.in.a.child.ontuberculosis.treatment.or.co-trimoxazole-induced.rash.in.a.child.receiving.CPT).Adverse.reactions.that.have.a.non-ARV.drug.etiology.do.not.require.the.ARV.drug.to.be.changed.However,.because.o.the.risk.o.potentially.lie-threatening.hepatotoxicity.
associated.with.NVP,.hepatic.dysunction.o.any.etiology.requires.careul.consideration.be.given.to.the.discontinuation.o.NVP.
Although.there.are.ewer.data.on.ARV.drug.toxicit y.in.children.than.in.adults,.the.ull.spectrum.o.ARV. toxicit ies. observed. in. adults. has. also. been. reported. in. children. (91). However,. some.toxicities.are.less.common.in.children.than.in.adults.(eg.NVP-related.symptomatic.hepatotoxicity.is.rare.in.children),.while.others.are.more.common.in.children.than.adults.(eg.EFV-related.rash).or.occur.only.in.children.(eg.TDF-related.loss.o.bone.density).More.attention.should.be.paid.to.pharmacovigilance.and.post-marketing.surveillance.in.paediatric.populations
Drug-related.adverse.events.may.be.acute,.occurring.soon.ater.a.drug.has.been.administered;.they.
may.be.subacute,.occurring.within.1.to.2.days.o.administration;.or.they.may.be.late,.occurring.ater.prolonged.drug.administration.Such.adverse.events.may.vary.in.severity.rom.mild.to.severe.and.lie-threatening.Experience.with.ARV.drugs.has.led.to.the.recognition.o.several.types.o.distinct.adverse.drug.eects.that.may.be.most.common.with.certain.ARV.drugs.or.drug.classes,.including:
. haematological.adverse.events.associated.with.drug-induced.bone-marrow.suppression,.most.commonly.seen.with.AZT.therapy.(anaemia,.neutropenia.and,.more.rarely,.thrombocytopenia);
. mitochondrial.dysunction,.primarily.seen.with.the.NRTI.drugs,.including.lactic.acidosis,.hepatic.toxicity,. pancreatitis. and. peripheral. neuropathy. (the. NRTIs. dier. in. their. ability. to. aect.
mitochondrial.unction,.d4T.having.greater.toxicity.than.AZT.and.3TC,.and.ABC.even.less.so);. lipodystrophy.and.metabolic.abnormalities,.primarily.seen.with.d4T.and.the.PI.class,.and.to.
a.lesser.degree.with.certain.other.NRTI.drugs.(abnormalities.include.at.maldistribution.and.body. habitus. changes,. hyperlipidaemia;. hyperglycaemia,. insulin. resistance,. diabetes.mellitus,.osteopaenia,.osteoporosis.and.osteonecrosis);
. allergic.reactions.such.as.skin.rashes.and.hypersensitivity.reactions,.more.common.with.the.NNRTI.drugs.but.also.seen.with.certain.NRTI.drugs,.such.as.ABC
Toxicity. can. be. monitored. clinically. on. the. basis. o. child/guardian. reporting. and. physical.
examination,. and. can. also. be. assessed. by. means. o. a. limited. number. o. laboratory. tests,.depending.on.the.specic.ARV.combination.regimen.that.is.utilized.and.the.health.care.setting.Routine.laboratory.monitoring,.although.desirable,.is.not.required.and.cannot.be.carried.out.in.many.decentralized.acilities
VIII. ANTIRETROVIRAL DRUG TOxICITY
7/30/2019 Anti Retroviral Therapy guidelines
35/152
2
The.management.o.the.patient.and.the.decision.about.the.potential.need.to.stop.drugs.or.to.
substitute (i ).a.new.ARV.drug.or.a.drug.associated.with.toxicity.largely.depends.on.the.ability.to.attribute.the.toxicity.to.a.specic.ARV.drug.in.the.treatment.regimen.and.on.the.severity.o.the.toxicity. symptoms. (Box. 7). Given. the. limited. number. o. ARV. drugs. and. drug. combinations.available.in.resource-limited.settings,.it.is.preerable.to.pursue.drug.substitutions.where.easible.so.to.avoid.premature.switching.to.completely.new.alternative.regimens,.and.to.restrict.drug.substitutions.to.situations.where.toxicity.is.severe.or.lie-threatening.
As.a.general.principle, mild toxicities.do.not.require.discontinuation.o.therapy.or.drug.substi tution,.and.symptomatic.treatment.may.be.given.(eg.antihistamines.or.a.mild.rash).Some.moderate.or.severe.toxicities.may.require.the.substitution.o.an.ARV.drug.associated.with.toxicity.by.a.drug.
in.the.same.ARV.class.but.with.a.dierent.toxicity.prole.(eg.peripheral.neuropathy).or.by.a.drug.in.a.dierent.class,.but.do.not.require.discontinuation.o.all.ART. Severe lie-threateningtoxicity. requires.discontinuation. o.all. ARV.drugs. and. the. initiation. o.appropriate. supportive.therapy.(such.as.intravenous.fuids),.depending.on.the.toxicity,.with.substitution.o.another.drug.or.the.one.associated.with.the.toxicity.once.the.patient.is.stabilized.and.the.toxicity.is.resolved.(see.Annex.F).NNRTI.drugs.have.a.much.longer.hal-lie.than.NRTIs,.leading.to.a.concern.that.stopping. all. drugs. simultaneously. results. in. exposure. to. drugs. rom. the. NNRTI. class. only.However,.i.a.child.has.a.lie-threatening.toxicity,.all.ARV.drugs.should.be.stopped.simultaneously.until.the.patient.is.stabilized.
Clinical.examination.can.also.detect.toxicities.that.are.not.lie-threatening.and.that.may.appear.late.(months.to.years.ater.therapy.has.been.started),.such.as.lipodystrophy.In.such.cases,.reerral.or.management.to.district.or.regional.hospital.centres.or.consultation.with.an.HIV.expert.is.recommended.
Regardless. o. their. severity,. adverse. events. may. aect. adherence. to. therapy. A. proactive.approach.to.managing.toxicity.is.recommended.Discussing.the.potential.side-eects.o.the.ART. regimen. beore. the. init iation. o. therapy.and.during. the.ear ly. stages.o. treatment.with. the.child.and.her/his.caregivers.as.well.as.support.during.minor.and.moderate.adverse.events,.can.increase.the.likelihood.o.adherence.to.therapy.(see.Section.XVI).The.child.and.the.caregivers.
should.be.amiliar.with.signs.o.toxicities.that.are.serious.and.require.immediate.contact.with.the.provider.and.potential.drug.discontinuation.This.is.particularly.important.or.toxicities.that.can.be.lie-threatening.i.the.ARV.drug.is.not.discontinued,.such.as.the.NVP-associated.Stevens-Johnson.syndrome,.symptomatic.hepatitis.or.the.ABC-associated.hypersensitivity.reaction
(i). Substitution.is.the.exchange.o.one.drug.in.a.(rst-line).regimen.or.another.(rst-line.regimen).drug;.this.is.dierent.rom.switching.a.drug.because.o.ailure.when.all.drugs.o.a.regimen.are.changed.to.a.dierent.(second-line).regimen.(see.Sections.IX.and.X)
7/30/2019 Anti Retroviral Therapy guidelines
36/152
30AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Box . Guiding principles in the management o ARV drug toxicity
1. Determine.the.seriousness.o.the.toxicity
2. Evaluate.concurrent.medications.and.establish.whether.the.toxicity.is.attributable.to.an.ARV.drug.or.to.a.non-ARV.medication.taken.at.the.same.time
3. Consider.other.disease.processes.(eg.viral.hepatitis.in.a.child.on.ARV.drugs.who.develops.jaundice).or.immune.reconstitution.syndrome,.because.not.all.problems.that.arise.during.treatment.are.caused.by.ARV.drugs
4. Manage.the.adverse.event.according.to.severity.In.general:
. Severe.life-threatening.reactions.(Annex.F):.Immediately.discontinue.all.ARV.drugs,.manage.the.medical.event.(ie.symptomatic.and.supportive.therapy).and.reintroduce.ARV.drugs.using.a.modied.regimen.(ie.with.an.ARV.substitution.or.the.oending.drug).when.the.patient.is.stabilizeda
. Severe.reactions:.Substitute.the.oending.drug.without.stopping.ARTa.
. Moderate.reactions:.Consider.continuation.o.ART.as.long.as.easible.I.the.patient.does.not.improve.on.symptomatic.therapy,.consider.single-drug.substitutionsa.For.a.ew.moderate.toxicities.(eg.peripheral.neuropathy.or.lipodystrophy).single.drug.substitution.needs.to.be.considered.earlier
. Mild.reactions.are.bothersome.but.do.not.require.changes.in.therapy
5. Stress.the.maintenance.o.adherence.despite.toxicity.or.mild.and.moderate.reactions.
6. I.there.is.a.need.to.discontinue.ART.because.o.lie-threatening.toxicity,.all.ARV.drugs.should.be.stopped.until.the.patient.is.stabilized.
a. Reer.to.Table.7.or.substitution.options
7/30/2019 Anti Retroviral Therapy guidelines
37/152
3
I.toxicity.is. related.to. an.identiable. drug. in.a. regimen. the. oending. drug. can. generally.be.
replaced.with.another.drug.rom.the.same.class.that.does.not.have.the.same.adverse.eect,.eg.substitution.o.d4T.or.AZT.(eg.or.anaemia).or.NVP.or.EFV.(eg.or.CNS.toxicity.or.in.the.event.o.pregnancy.in.adolescent.girls).Given.the.limited.number.o.ARV.drug.options.available.in.resource-limited. settings,. drug. substitutions. should. be. limited. to. situations. where. toxicity. is.severe.or.lie-threatening.(see.Annex.F).For.reasons.o.toxicity.the.substitution.o.drugs.rom.the.PI.class.should.be.avoided.i.possible.Table.7.lists.the.usual.ARV.substitution.options.or.adverse.events.or.the.recommended.combination.rst-line.regimens.
For.some.lie-threatening.toxicities.it.may.not.be.possible.to.identiy.an.optimal.substitute.drug.For.example,.in.respect.o.NVP-associated.Stevens-Johnson.syndrome,.most.clinicians.would.
avoid.substituting.another.NNRTI.drug.(eavirenz).because.o.the.potential.or.class-specic.toxicity.This.would.require.a.change.to.either.a.triple.NRTI.regimen.(eg.substituting.a.third.NRTI,. such. as.ABC,.or. NVP),.or. substituting. a.protease.inhibitor. ARV.drug.or. NVP,.thereby.introducing.a.drug.class.usually.reserved.or.second-line.regimens.
Ix. SUbSTITUTING WITHIN A FIRST-LINE ANTIRETROVIRAL DRUGREGImEN IN INFANTS AND CHILDREN bECAUSE OF DRUG TOxICITY
7/30/2019 Anti Retroviral Therapy guidelines
38/152
32AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Table . Severe toxicities in inants and children associated with specic rst-
line antiretroviral drugs and potential rst-line drug substitutions
First-lineARV drug
Most requent signicanttoxicity or the ARV drug
Suggested rst-line ARV drugsubstitution
ABC Hypersensitivity.reaction AZT
AZT Severe.anaemiaa.or.neutropeniab d4T.or.ABC
Lactic.acidosis ABCd.
Severe.gastrointestinal.intolerancec
d4T.or.ABCd4T Lactic.acidosis ABCd.
Peripheral.neuropathy AZT.or.ABCe
Pancreatitis
Lipoatrophy/metabolic.syndrome ABC.
EFV Persistent.and.severe.central.nervous.system.toxicity g
NVP
Potential.teratogenicity.(adolescent.girl.in.rst.trimester.o.pregnancy,.or.o.childbearing.potential.and.not.receiving.adequate.contraception)
NVP Acute.symptomatic.hepatitish EFV i
Hypersensitivity.reaction Preerred.substitution.o.NVP.to:.. a.third.NRTI.(disadvantage:.may.
be.less.potent). or
. PI.(disadvantage:.premature.start.o.class.usually.reserved.or.second-line)k
Severe.or.lie-threatening.rash.(Stevens-Johnson.syndrome) j
Note:.3TC/FTC-associated.pancreatitis.has.been.described.in.adults.but.is.considered.very.rare.in.children.a. Exclude.malaria.in.areas.o.stable.malaria,.severe.anaemia.is.dened.as.Hb.
7/30/2019 Anti Retroviral Therapy guidelines
39/152
33
Poor.adherence,.inadequate.drug.levels,.prior.existing.drug.resistance.or.inadequate.potency.o.
the.drugs.chosen.can.all.contribute.to.ARV.treatment.ailure(83-86).Genetic.dierences.in.drug.metabolism.may.also.be.important.(92,.93).It.is.recommended.that.programmes.primarily.use.clinical.criteria,.supported,.where.possible,.with.CD4.criteria,.in.order.to.identiy.treatment.ailure.When. treatment. ailure. is. conrmed,. switching. to. a. new. second-line. regimen. becomes.necessary(i )
It.should.not.be.concluded,.on.the.basis.o.clinical.criteria,.that.an.ARV.regimen.is.ailing.until.the.child.in.question.has.had.a.reasonable.trial.on.the.therapy,.ie.the.child.should.have.received.the. regimen. or. at. least. 24. weeks,. adherence. to. therapy. should. have. been. assessed. and.considered.to.be.optimal,.and.any.intercurrent.opportunistic.inections.should.have.been.treated.
and.resolved,.and.immune.reconstitution.infammatory.syndrome.(IRIS).excluded.Additionally,.beore.considering.a.change.in.treatment.because.o.growth.ailure.it.should.be.ensured.that.the.child.is.receiving.adequate.nutrition.
Clinical denition o treatment ailure
The.detection.o.new.or.recurrent.clinical.events.classied.within.the.WHO.clinical.staging.may.also.refect.progression.o.disease.when.a.child.is.on.ART.Treatment.ailure.should.be.considered.when.either.new.or.recurrent.stage.3.or.4.clinical.events.develop.in.a.child.on.therapy.(Table.8)
Immune reconstitution infammatory syndrome
Clinical.disease.progression.should.be.dierentiated.rom.the.IRIS,.an.entity.that.has.been.observed.in.adults.and.less.requently.in.children.starting.ART,.particularly.those.with.very.low.CD4.values.(97-102).Symptoms.are.similar.to.those.seen.in.opportunistic.inections.They.usually.occur.within.the.rst.three.months.ater.the.start.o.potent.ART.(103),.concurrent.with.a.rapid.rise.in.CD4.values.It.is.also.possible.that.immunological.reconstitution.may.lead.to.the.development.o.atypical.presentations.o.some.opportunistic.inections.
(i). Switching.a.regimen.or.a.ailure.should.not.be.conused.with.substitution.o.a.single.drug.or.toxicity.(see.Section.IX)
x. SWITCHING AN ARV REGImEN IN INFANTS AND CHILDREN:TREATmENT FAILURE
7/30/2019 Anti Retroviral Therapy guidelines
40/152
34AntiretrovirAl therApy of hiv infection in infAnts And children:
towArds universAl Access
Table 8. Using the WHO Paediatric Clinical Staging to guide decision-making
on switching to second-line therapy or treatment ailure
New or recurrentevent on ART a, b
Management options c, d
[A (IV)]
No.new.events.or.PGL..(T1).
. Do.not.switch.to.new.regimen. Maintain.regular.ollow.up.
Stage.2.events
(T2)
. Treat.and.manage.staging.event. Do.not.switch.to.new.regimen
. Assess.and.oer.adherence.support.. Assess.nutritional.status.and.oer.support.. Schedule.earlier.visit.or.clinical.review.and.consider.CD4
Stage.3.events
(T3)
. Treat.and.manage.staging.event.and.monitor.responsee
. Check.i.on.treatment.24.weeks.or.more.. Assess.and.oer.adherence.support.. Assess.nutritional.status.and.oer.support.. Check.CD4...where.available.. Institute.more.requent.ollow-up
. Consider.switching.regimen.
Top Related